Stakeholder Communication　|　PharmaEngine, Inc.

Stakeholder Identification

In purusing sustainable development, PharmaEngine deeply understands the importance of stakeholder relations and the continuance of our social commitments. We hope to have a transparent and effective communication channel with our stakeholders. We have identified major stakeholder themes using the following six-step procedure:

Major Themes and Boundaries

Major Theme	SDGs	Management Policy	Border Line
Major Theme	SDGs	Management Policy	Internal	External
Innovative R&D	SDG8 Decent Work and Economic Growth	Continue to develop competitive and diverse unmet needs drugs Ensure product quality, safety and compliance	PharmEngine Employees	Shareholders Investors In-license or out-license partners Customers Suppliers and CROs
Cyber Security	SDG9 Industry, Innovation and Infrastructure	Set up secure information security equipment and management processes	PharmEngine Employees	Shareholders Investors Customers Suppliers and CROs
Corporate Governance	SDG16 Peace, Justice and Strong Institutions SDG17 Partnerships for the Goals	Incorporate ESG in operation policies Strengthen the auditing mechanism and strictly prohibit misconduct that endangers the Company Strengthen internal communication and operation model	PharmEngine Employees	Shareholders Investors Customers Suppliers and CROs Government agencies Media
Industry Cooperation	SDG17 Partnerships for the Goals	Drive suppliers or other cooperative units to actively conduct ESG actions	PharmEngine Employees	Suppliers and CROs
Environment Protection	SDG7 Affordable and Clean Energy SDG12 Responsible Consumption and Production SDG13 Climate Action	Reduce the waste of energy resources and introduce effective energy and resource improvement equipment or policies Introduce circular economy to reduce waste Strengthen the initiatives on climate and environmental issues, and enhance awareness of colleagues and cooperative units	PharmEngine Employees	Customers Suppliers and CROs Communities Government agencies
Social Engagement	SDG3 Good Health and Well-Being	Enhance care for social and human rights issues, and continuously track follow up results Care for patients and medical institutions, and construct friendly social services	PharmEngine Employees	Customers Communities Charity groups
Employee Training	SDG4 Quality Education SDG8 Decent Work and Economic Growth SDG10 Reduced Inequalities	Focus on employee career growth and plan a clear functional development blueprint Protect human rights and create a good working environment	PharmEngine Employees	Customers Government agencies

Stakeholder Communication

The Company has always adhered to a sound business strategy and financial operation, and has protected the rights or interests of stakeholders, responding to issues of concern to stakeholders at shareholder meetings, board meetings, internal company meetings, labor-management meetings, participation in public welfare activities, participation in union activities, and internal and external company websites. The Company's Sustainability Promotion Taskforce operates in accordance with the "P-D-C-A" (Planning-Execution-Audit-Action) management model to identify stakeholders and collect and review issues of concern to stakeholders. In order to ensure the implementation of various major issues and the achievement of goals, the Sustainability Promotion Taskforce regularly discusses major economic, social and environmental issues, the achievement of goals of each unit and the formulation of future directions every quarter, and compiles relevant results data, the results of discussions with stakeholders and sustainable discussion suggestions for review by the Audit Committee members, and submits reports to the board of directors for confirmation every year. The 2024 sustainable performance (including communication with stakeholders) and the 2025 sustainable action plan have been reported to the Board of Directors on October 30, 2024. The communication and report contents of each category of stakeholders in the most recent year are as follows:

Stakeholder	Key Issue	Communication Channel and Frequency	2023 Engagement
Shareholders and Investors	Operating and financial status Business performance Corporate governance Risk management	Shareholders’ meeting/once every year Investors’ conference/once every quarter MOPS/every time Regular announcement of financial statements (annual report)/every quarter (year) Stock agency/ every time Information disclosed online/every time Answer investors’ questions by phone or email/every time	Held institutional investors' conferences and roadshows 5 times Held shareholders' meeting 1 time and board meetings 4 times
Employees	Welfare policy Labor relations Labor rights Training Workplace health and safety	Labor conferences/once a quarter Internal website/permanent Welfare Committee/permanent Employee feedback line and mailbox/every time Regular fire safety propaganda provided by the building management committee/every time Annual health checkup/once every two years Satisfaction survey/once every two years	Held labor-management meetings 5 times Discussed date and location of Family Day and the annual company trip, and promoted "Employee Leave and Travel Subsidy Program" Promoted "Employee Health Check Care Program"
In-license or Out-license Partners	Operating and financial status Business performance Risk management Legal compliance	E-mail/every time Visits, meetings, and teleconferences/once a quarter	Held group meetings regularly
Customers	Product quality and safety Service quality Marketing communications Customer rights, interests, and data privacy	Telephone or e-mail/every time Unscheduled patient meetings/every event Regular participation in medical associations/every time Academic seminars/every time Product information disclosed online/permanent	6 pancreatic cancer patient meetings Product introduction in medical centers and hospitals 2024 World Pancreatic Cancer Day activities
Drug Development Partners (Product Storage and Logistics Vendors)	Sustainable procurement Communication policy	Unscheduled visits and audits/twice every year Telephone or e-mail/every time	Visits 2 times Audited by e-mail
Supplier	Product quality and safety Sustainable procurement Communication policy	Unscheduled visits and audits/once a year Telephone or e-mail/every time Communicate with vendor via procurement staff/every time	2 GxP supplier capability assessments before cooperation Audited by e-mail Online meeting Online audit
Community and Charity Groups	Charities and fundraising Community care Environmental management Legal compliance	Contact the charities by the event organizer/every time Contact by welfare committee members/every time Industry-academic cooperation	Visually impaired massages Continued to support "Do One Thing for Tamsui River" by promoting the history of Tamsui and water conservation Held events for ESG Participated in HOPE Foundation event as volunteers Donated Christmas presents to disadvantaged children in Hualien County Held sessions with students in 2 universities to share industry experience
Government Agencies	Legal compliance Labor relations Participation in public policy	Competent authority meetings and participate in related seminars/every time	Contacted the Industrial Development Administration by phone and e-mail Contacted DOIT by phone and e-mail Contacted National Taxation Bureau of Taipei by phone and e-mail
Media	Business performance Operating and financial status Legal compliance	Press release/every time Spokesperson system/permanent Information disclosed online/every time Public relations Department/permanent	Material information and press releases were issued 29 times

Responses and Responsibilities to Stakeholders

To achieve sustainability, we constantly communicate with stakeholders to understand their needs and use that information as reference of the company policy and business development. We listen to the opinion feedback of the stakeholders as a follow-up to improve the subject during the policy and plan implementation process.

We presented and communicated our "Report on Most Concerned Issues Stated by Stakeholders" during the Board of Directors meeting on July 25, 2024. The report covered the various issues raised by the stakeholders.

Improvements on Stakeholders' Communication

The Company evaluates annual improvement plans based on company resources and benchmark companies. In 2024, the Company made the following improvements: established cyber security policies, obtained ISO27001 Information Security certification with third-party verification and obtained certification for the updated version of the ISO 27001, uploaded non-edited video recordings for AGM and quarterly investors' conference in 2024, recorded questions asked by shareholders in 2024 AGM and included them in the 2023 AGM Meeting Minutes, disclosed the Company's water usage and waste generated data, and also disclosed GHG emissions inventory (scope 1 & 2) for the past two years (2022-2023) and obtained third-party assurance, initiated and completed the data collection and analysis of first phase scope 3 GHG emission inventory, regularly assessed the independence and eligibility of certified accountants using Audit Quality Indicators (AQIs) by the Board, and made resolutions on green energy procurement and changed all office lighting to LED lighting, etc.

Stakeholder Contact Information

Stakeholder	Contact Person	Telephone	E-mail
Shareholders and Investors/Media/Government Agencies	Company Spokesperson ChiHsing Chang, Vice President	(02) 2515-8228	info@pharmaengine.com
Employees/Communities and Charity Groups	President & CEO Office, Human Resources Melody Lin, Director	(02) 2515-8228	melodylin@pharmaengine.com
Partnering	Corporate Development, Business Development Roger Hsieh, Associate Director	(02) 2515-8228	roger.hsieh@pharmaengine.com
Drug Development Partners	Research and Development, Medicinal Chemistry & CMC Mel Liu, Ph.D., Director	(02) 2515-8228	mel.liu@pharmaengine.com
Suppliers/Product Storage and Logistics Vendors	President & CEO Office, Quality Assurance Ken Chou, Manager	(02) 2515-8228	ken.chou@pharmaengine.com
Customers	Marketing & Sales, Sales & Product Development April Chiu, Associate Director	(02) 2515-8228	april.chiu@pharmaengine.com
Whistleblower Hotline	Independent Directors/Audit Office	(02) 2515-8228	audit@pharmaengine.com